Skip to main content

Table 2 Baseline characteristics and outcome measures after natural dendritic cell vaccination

From: The clinical application of cancer immunotherapy based on naturally circulating dendritic cells

  

pDC-MEL1

mDC-MEL1

mDC-PROS2

Cancer type

 

Melanoma

Melanoma

Prostate

Patients

Male/female

10/5

10/4

12/0

Age, years

Median (range)

52 (35–69)

50 (31–73)

69.5 (52–78)

Disease stage

M1a

1

4a

2

M1b

8

2

5

M1c

6

9

3

Unknown

0

0

2

Line of systemic treatment

1st line

14

14

0

2nd line or later

1

0

12b

Number of vaccines received

2 or 3

12

9

12

6

2

2

–

9

1

3

–

Vaccine-specific toxicity

Grade 1

6

4

n.a.

Grade 2

0

1

n.a.

Immunological responses

Control antigenc (blood)

T-cell: 10/14

Ab: 12/15

T-cell. 11/13

Ab: 4/13

T-cell: n.t.

Ab: 4/12

Control antigen (DTH)

n.t.

n.t.

4/12d

Tumor antigen (blood)

7/15e

4/12

0/12

Tumor antigen (DTH)

2/15

4/13

0/12d

Progression-free survival

Median (range; months)

4.0 (< 4–20)

2.8 (< 4–67+)

n.a.

Overall survival

Median (range; months)

22.3 (< 4–64)

13.3 (< 4–67+)

18 (6–40+)

  1. aIncluding 1 irresectable stage III melanoma patient
  2. bAll patients received 2–4 lines of hormonal treatment. Four patients received prior chemotherapy
  3. cT-cell proliferation upon stimulation with the control antigen (T-cell) and control antigen-specific antibodies (Ab) are shown
  4. dSkin reaction tested only
  5. eNo tumor-specific T-cells were detected prior to restimulation
  6. Abbreviations: n.a., not available; n.t., not tested